Navigation Links
Mylan One of First to Launch Generic Version of Boniva®
Date:3/20/2012

PITTSBURGH, March 20, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Ibandronate Sodium Tablets, 150mg. This product is the generic version of Roche's Boniva®, which is indicated for the treatment and prevention of osteoporosis in postmenopausal women.

Boniva® had U.S. sales of approximately $517 million for the 12 months ending Dec. 31, 2011, according to IMS Health. Mylan is shipping the product immediately.

Currently, Mylan has 173 ANDAs pending FDA approval representing $100.9 billion in annual sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $27.4 billion in annual brand sales, for the 12 months ending December 31, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Canada Receives Health Canada Approval for Generic Version of Crestor®
2. Mylan Continues to Pursue Damages and Injunction Against Sunovions Brovana® in Ongoing Litigation
3. Mylan Pharmaceuticals President Tony Mauro Elected Chairman of GPhA
4. Mylan Secures an Additional $300 Million of Committed Financing
5. Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year
6. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement
7. Mylan to Change Name of Specialty Subsidiary From Dey Pharma to Mylan Specialty
8. Mylan Actively Addressing Shortage of Preservative-Free Methotrexate Injection
9. Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers
10. Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant
11. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ...
(Date:1/15/2014)... Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), a ... a non-invasive, wireless continuous glucose monitoring system, today announced ... Interim CEO of Echo Therapeutics, will present at "TEN", ... Mr. Doman will make a corporate presentation ...
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Thomas, McNerney & Partners, LLC, a health care venture ... technology companies, will be relocating its West Coast office ... Pratik Shah, Ph.D. announced the move at BIOCOM,s first ... "Southern California is home to many top-tier scientific ...
... 2011 Healthpoint today announced the launch of a ... Biotherapeutics, along with an updated brandmark and corporate tagline, ... is designed to communicate the company,s commitment to scientific ... contribute to improved outcomes and quality of life for ...
Cached Medicine Technology:Thomas, McNerney & Partners Expands Team and Moves West Coast Office to San Diego 2Healthpoint Launches New Corporate Identity 2Healthpoint Launches New Corporate Identity 3
(Date:4/17/2014)... NEW YORK (17 April 2014) Population Council scientists and ... is safe, stable, and can prevent the transmission of ... and rectum in animals: HIV, herpes simplex virus 2 ... provides the first data that the gel is effective ... of efficacy in the vagina against all three viruses ...
(Date:4/17/2014)... flow and alleviates muscle soreness after exercise, according ... of Illinois at Chicago. , The study, reported ... Archives of Physical Medicine and Rehabilitation , also ... who had not exercised, suggesting that massage has ... physical activity. , Improved circulation and relief of ...
(Date:4/17/2014)... TORONTO, April 17, 2014While 94 per cent of Canadians ... that screen newborns for a specific number of genetic ... willing to participate in screening that would sequence their ... prick test" in their first day or two of ... taken from their heels and tested for about five ...
(Date:4/17/2014)... lost its status as the leading weapon against the ... life, with new research indicating it simply needs to ... use of the cheap anti-malarial drug chloroquine in treating ... of more than half a million people each year ... has developed resistance to chloroquine, but research carried out ...
(Date:4/16/2014)... , PHOENIX, Ariz. April 15, 2014 The ... Arizona philanthropists at their annual Founders Dinner for their ... cancer. The event took place March 28 in Scottsdale. ... & Catherine Ivy Foundation, received TGen,s John S. McCain ...
Breaking Medicine News(10 mins):Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:Scientists find new way to fight malaria drug resistance 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... Pa., June 1 Practice-Reps, LLC ( http://www.practice-reps.com ) ... to specialty medical practices along the East Coast. The ... a 16-year veteran of the practice marketing industry, to ... experienced marketing support on a part-time basis. , ...
... SAN FRANCISCO, Calif., June 1 Rigel Pharmaceuticals, Inc. ... oral Syk inhibitor, R788, is being evaluated in a ... the National Cancer Institute (NCI), part of the U.S. ... trial will include patients with advanced colorectal, thyroid, non-small ...
... , Collaboration Delivers Cost and Quality Benefits for Widespread ... June 1 SAFC(R) ( www.safcglobal.com ), a member ... and Cherokee Pharmaceuticals(TM) ( www.cherokee-pharma.com ... business, today announced an exclusive strategic partnership that encompasses ...
... , New Product Names for Recently Introduced MicroRNA-based Diagnostics ... Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic ... platform yesterday at the American Society of Clinical Oncology ... a presentation entitled "Profiling of Receptor Tyrosine Kinases (RTK) ...
... the mouth and periodontists to ask questions about heart health ... leading killer of men and women in the United States, ... each day. Periodontal disease, a chronic inflammatory disease that destroys ... 75 percent of Americans and is the major cause of ...
... program aimed at reducing criminal behavior in juvenile justice teens ... reducing the teens, rate of pregnancy, according to a new ... in the Department of Psychology at Oregon State University, and ... Learning Center, conducted the research, which will be published in ...
Cached Medicine News:Health News:Practice-Reps Brings Sales and Marketing to the Business of Medical Practice Management 2Health News:Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers 2Health News:Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers 3Health News:SAFC(R) & Cherokee Pharmaceuticals(TM) Pool Expertise and Resources With Strategic Partnership For U.S. Market 2Health News:SAFC(R) & Cherokee Pharmaceuticals(TM) Pool Expertise and Resources With Strategic Partnership For U.S. Market 3Health News:Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting 2Health News:Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting 3Health News:Healthy Gums and a Healthy Heart: The Perio-Cardio Connection 2Health News:Healthy Gums and a Healthy Heart: The Perio-Cardio Connection 3Health News:Healthy Gums and a Healthy Heart: The Perio-Cardio Connection 4Health News:Intervention reduces delinquent teenage pregancy rates 2Health News:Intervention reduces delinquent teenage pregancy rates 3
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... ergonomics, and value!, Comfortable feel ... non-slip, contoured handle , Finer control ... spring action , Completely autoclavable for ... need for recalibration , Easy-to-read precision ...
Inquire...
Medicine Products: